Strategic line 4 is called ‘Advanced Therapies’. This line promotes the development of advanced therapies in key areas such as cancer, immune-mediated diseases and rare diseases. It also seeks to foster the creation of spin-offs and the establishment of strategic alliances with industry, favouring innovation and the development of high-impact therapeutic solutions.

Through this strategic line, GENyO will optimise the implementation of advanced therapies, ensuring that they are more efficient, safer and more accessible. This will contribute significantly to improving the quality of life of patients and to achieving concrete advances in the treatment of various diseases.

Research Groups

Within the line dedicated to Advanced Therapies, we can find the following associated research groups: